Aadi Bioscience Inc. (AADI)
3.25
0.25 (8.51%)
At close: Jan 15, 2025, 3:59 PM
3.20
-1.54%
After-hours Jan 15, 2025, 06:55 PM EST
Company Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.
Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.
The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Aadi Bioscience Inc.
| Country | United States |
| IPO Date | Feb 16, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | David J. Lennon Ph.D. |
Contact Details
Address: 17383 Sunset Boulevard Pacific Palisades, California United States | |
| Website | https://aadibio.com |
Stock Details
| Ticker Symbol | AADI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422142 |
| CUSIP Number | 00032Q104 |
| ISIN Number | US00032Q1040 |
| Employer ID | 61-1547850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David J. Lennon Ph.D. | President, Chief Executive Officer & Director |
| Scott M. Giacobello CPA | Chief Financial Officer, Treasurer, Investor Relations & Corporate Communications |
| Bryan Ball | Chief Technical Operations Officer |
| Raymond G. Steitz | Senior Vice President of Human Resources & Chief Human Resources Officer |
| Stephen M. Rodin J.D. | Senior Vice President of Legal & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | SCHEDULE 13D | Filing |
| Dec 30, 2024 | DEFA14A | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 3 | Filing |
| Dec 23, 2024 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 23, 2024 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 20, 2024 | DEFA14A | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |